News Archive

  • Sask.-based research offers hope in unsettling times

    Uncertain times require robust social sciences and humanities analysis, and leadership from scholars to discuss complex issues with the public.

  • Saskatchewan Blue Cross invests $150K to help establish USask’s VIDO as Canada’s Centre for Pandemic Research

    The Vaccine and Infectious Disease Organization at the University of Saskatchewan is one step closer to establishing its Centre for Pandemic Research, thanks to a $150,000 donation from Saskatchewan Blue Cross.

  • Ministers Champagne, Joly and Carr highlight Budget 2021 biomanufacturing investments

    Budget 2021 proposes to provide $59.2M to USask's VIDO, through Western Economic Diversification Canada’s Regional Economic Growth through Innovation program, to help it develop and manufacture bio-solutions such as vaccines and therapeutics.

  • Federal budget supports USask’s VIDO with $59.2M

    Today the Government of Canada announced $59.2 million to VIDO to support the development of its vaccine candidates and the expansion of its research facilities, including a National Centre for Pandemic Research.

  • USask researchers seek to prevent liver disease, high blood pressure, and understand lifelong impacts of Zika virus

    Three University of Saskatchewan researchers have been awarded a total of $1.87 million by the Canadian Institutes for Health Research (CIHR) for projects involving fatty liver disease, high blood pressure, and Zika virus.

  • Canada’s Global Nexus and VIDO join forces to combat COVID–19

    Canada’s Global Nexus for Pandemics and Biological Threats at McMaster University and VIDO at USask are working together to accelerate vaccine and drug development, human clinical trials and create new diagnostic tools.

  • VIDO gains provincial support towards becoming a ‘Centre for Pandemic Research’

    The Government of Saskatchewan committed $15 million to support the University of Saskatchewan’s Vaccine and Infectious Disease Organization’s position as a Centre for Pandemic Research.

  • USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV

    The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization at the University of Saskatchewan.

  • New support to produce COVID-19 vaccines and treatments in Canada

    Prime Minister Justin Trudeau's announcement regarding new support to produce #COVID19 vaccines and treatments in Canada:

  • USask livestock research receives significant investment to advance industry

    Saskatchewan’s Agriculture Development Fund will provide more than $6.5 million to support livestock research efforts at USask including $1.58 million for VIDO.